$245.49 3.83 (1.58%)
19:45 EST AMGN Stock Quote Delayed 30 Minutes
Previous Close -
Market Cap 162.44B
PE Ratio 77.93
Volume (Avg. Vol.) 2.86M
Day's Range 240.02 - 246.84
52-Week Range 177.05 - 264.97
Dividend & Yield 5.28 (2.15%)
AMGN Stock Predictions, Articles, and Amgen News
- From InvestorPlace
- From the Web
Here are seven cheap stocks with solid businesses that may power portfolios in 2021
For those who are put off by the extreme enthusiasm of this bull market, the usually reliable Dow Jones stocks offer much-needed balance. Here are seven to consider.
Biotech stocks are vulnerable to headlines, but these three have too much potential to ignore. Own them for a swing trade into 2021.
In a market made up of individual companies, three fresh Dow Jones stocks are showing a close vote, with bulls and bears in on the action.
The company has had some challenges. But when looking at the long-term, Amgen stock looks like a good play.
Alexandria Real Estate Equities is the largest landlord in the US for laboratories and related offices.
These four strong California stocks deserve your attention and further due diligence to be included in long-term portfolios.
There is ridiculously big upside potential for Chinese biotech stocks in the next decade. The spread of the pandemic has only strengthened the case.
As the world and the markets continue to grapple with the effects of the novel coronavirus outbreak, these innovative healthcare stocks to buy look poised for success.
Biotech stocks pulled off an impressive rally to finish 2019 strong. These names in the industry are looking to do the same in 2020.
Here are three of the best healthcare stocks to buy, as the sector is flashing a 'buy-the-dip' setup to kick off the New Year.
Matt McCall predicts that 2020 will be a better year for U.S. cannabis stocks. He's also calling for a big rally in bitcoin.
Goldman Sachs analysts came out with three conviction buys on Monday. Here's what else happened in the stock market today.
Folks who haven’t been paying attention to the absolutely huge potential happening in biotech stocks right now -- both in the U.S. and other parts of the world -- have been put on notice.
The biggest risk to Amgen stock comes from health reform that might limit the number of drugs insurers pay for, creating price competition.
Biotech stocks are still out of favor because of macro uncertainties. But beneath that, investors may find companies trading at deep value.
The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations
Navellier RatingsPowered by Portfolio Grader